Compositions and methods for the treatment of threatened respiratory failure caused by coronavirus infection and disease
View Patent ↗A method of treating a coronavirus infection involves administering an inhibitor of the Neu1 sialidase-G protein-coupled receptor-Matrix metalloproteinase 9 (Neu1-GPCR-MMP9) signaling platform, in particular administering intravenously or by inhalation to a patient infected with COVID-19 and its variants a therapeutically effective amount of oseltamivir phosphate, preferably in conjunction with the oral administration of aspirin, in order to reduce the symptoms of respiratory compromise and/or prevent Acute Respiratory Distress Syndrome (ARDS).
1 . A method of treating a coronavirus infection or suspected coronavirus infection comprising administering intravenously or via inhalation to a patient in need thereof a therapeutically effective amount of oseltamivir phosphate, wherein the oseltamivir phosphate inhibits mammalian neuraminidase-1.
2 . A method of treating or preventing acute respiratory distress syndrome (ARDS) comprising administering intravenously or via inhalation to a patient in need thereof a therapeutically effective amount of oseltamivir phosphate, wherein the oseltamivir phosphate inhibits mammalian neuraminidase-1.
3 . The method of claim 2 , wherein the patient is diagnosed with a coronavirus infection.
4 . The method of claim 2 , wherein the patient is diagnosed with sepsis.
5 . The method of claim 1 , wherein the coronavirus is COVID-19.
6 . The method of claim 1 , wherein the patient has atelectasis and/or hypoxemia.
7 . The method of claim 1 , wherein the patient has one or more symptoms of respiratory compromise selected from shortness of breath, rapid breathing, and bluish skin coloration.
8 . The method of claim 7 , wherein the method ameliorates or alleviates one or more of symptoms selected from shortness of breath, rapid breathing, and bluish skin coloration.
9 . The method of claim 1 , comprising administering oseltamivir phosphate at a daily dose of between 100 mg and 1000 mg intravenuously or via inhalation.
10 . The method of claim 1 further comprising administering a therapeutically effective amount of aspirin to the patient.
11 . The method of claim 10 , wherein the aspirin is administered orally concurrently with the oseltamivir phosphate administered intravenously or via inhalation.
12 . The method of claim 10 , wherein the aspirin is administered orally at a daily dose of between 100 mg and 1000 mg.
13 . The method of claim 1 comprising:
administering to the patient a bolus dose of between 100 mg and 1000 mg of oseltamivir phosphate by intravenous injection or inhalation;
subsequently administering an additional dose of between 100 mg and 1000 mg of oseltamivir phosphate over 24 hours by continuous infusion; and orally administering to the patient aspirin at a dose of between 100 mg and 1000 mg.
14 . The method of claim 2 , further comprising concurrently orally administering a therapeutically effective amount of aspirin to the patient.
15 . The method of claim 1 , comprising administering intravenously an effective amount of oseltamivir phosphate.
16 . The method of claim 2 , wherein administering the therapeutically effective amount of oseltamivir phosphate decreases the plasma/serum level of one or more of IL-6, TNFα, G-CSF, MCP-1, and MIP-1a pro-inflammatory cytokines by ≥5%, ≥10% or ≥25% within 24 hours.
17 . The method of claim 1 , wherein administering the therapeutically effective amount of oseltamivir phosphate decreases viral load by ≥5%, ≥10% or ≥25% within 24 hours.